# HCW11-018b

Source: https://onco.cc/drugs/hcw11-018b/  
OnCo record `hcw11-018b` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HCW11-018b is an experimental injection under the skin designed to direct the body's T cells against solid tumours. HCW Biologics plans to ask the US regulator in 2027 for permission to begin its first trial in people.

## Summary

HCW11-018b is an investigational tetravalent T-cell engager from HCW Biologics, administered by subcutaneous injection and developed to treat solid tumours. HCW Biologics' 2026 S-1 states that after a Type B pre-IND meeting with the FDA in July 2026 the company received direction on preparing to start a Phase 1 trial in solid tumours, with the IND planned for the first half of 2027. The filing does not name the tumour antigen or the tumour types.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: HCW11-018b
- Modality: Tetravalent T-cell engager (fusion protein, subcutaneous)
- Mechanism: A tetravalent T-cell engager given by subcutaneous injection, as HCW Biologics' filing describes it: a multi-armed fusion molecule built to bring T cells into contact with tumour cells. The filing does not name the tumour antigen.

## Sources

- SEC EDGAR: HCW Biologics S-1, October 2026: https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm

## Connected records

- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- companies: [HCW Biologics](https://onco.cc/companies/hcw-biologics/)

---
JSON: https://onco.cc/api/v1/entities/hcw11-018b.json